{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T16:44:52Z","timestamp":1764175492455,"version":"3.41.2"},"reference-count":18,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2023,9,22]],"date-time":"2023-09-22T00:00:00Z","timestamp":1695340800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,10,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Data on antifungal susceptibility of Cryptococcus neoformans are limited in Japan. A total of 89 C. neoformans strains isolated from 83 non-human immunodeficiency virus-infected patients with cryptococcosis between 1997 and 2021 in Nagasaki, Japan, were investigated. Using the reference method M27-Ed4 by the Clinical and Laboratory Standards Institute, the minimum inhibitory concentration for 90% of isolates of fluconazole, itraconazole, voriconazole, amphotericin B, and flucytosine were 4, 0.125, 0.06, 0.5, and 4\u00a0\u00b5g\/ml, respectively, which were below the reported epidemiological cutoff values, without any detectable non-wild-type strains. Our findings imply no increasing trend of antifungal-resistant C. neoformans in Nagasaki, Japan.<\/jats:p>","DOI":"10.1093\/mmy\/myad100","type":"journal-article","created":{"date-parts":[[2023,9,23]],"date-time":"2023-09-23T04:45:53Z","timestamp":1695444353000},"source":"Crossref","is-referenced-by-count":1,"title":["Antifungal susceptibility profiles of <i>Cryptococcus neoformans<\/i> strains clinically isolated from non-HIV-infected patients in Nagasaki, Japan"],"prefix":"10.1093","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-9468-6051","authenticated-orcid":false,"given":"Nobuyuki","family":"Ashizawa","sequence":"first","affiliation":[{"name":"Infection Control and Education Center, Nagasaki University Hospital , 1-7-1 Sakamoto, Nagasaki 852- 8501 , Japan"},{"name":"Department of Respiratory Medicine, Nagasaki University Hospital , 1-7-1 Sakamoto, Nagasaki 852-8501 , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0696-5386","authenticated-orcid":false,"given":"Takahiro","family":"Takazono","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Nagasaki University Hospital , 1-7-1 Sakamoto, Nagasaki 852-8501 , Japan"},{"name":"Department of Infectious Diseases, Nagasaki University Graduate School of Biomedical Sciences , 1-7-1 Sakamoto, Nagasaki 852-8501 , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuya","family":"Ito","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Nagasaki University Hospital , 1-7-1 Sakamoto, Nagasaki 852-8501 , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nana","family":"Nakada","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Nagasaki University Hospital , 1-7-1 Sakamoto, Nagasaki 852-8501 , Japan"},{"name":"Health Center, Nagasaki University , 1-14 Bunkyo, Nagasaki 852-8521 , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuro","family":"Hirayama","sequence":"additional","affiliation":[{"name":"Department of Pharmacotherapeutics, Nagasaki University Graduate School of Biomedical Sciences , 1-7-1 Sakamoto, Nagasaki 852-8501 , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuaki","family":"Takeda","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Nagasaki University Hospital , 1-7-1 Sakamoto, Nagasaki 852-8501 , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shotaro","family":"Ide","sequence":"additional","affiliation":[{"name":"Infectious Diseases Experts Training Center, Nagasaki University Hospital , 1-7-1 Sakamoto, Nagasaki 852-8501 , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Iwanaga","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Nagasaki University Hospital , 1-7-1 Sakamoto, Nagasaki 852-8501 , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masato","family":"Tashiro","sequence":"additional","affiliation":[{"name":"Infection Control and Education Center, Nagasaki University Hospital , 1-7-1 Sakamoto, Nagasaki 852- 8501 , Japan"},{"name":"Department of Infectious Diseases, Nagasaki University Graduate School of Biomedical Sciences , 1-7-1 Sakamoto, Nagasaki 852-8501 , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Hosogaya","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Nagasaki University Hospital , 1-7-1 Sakamoto, Nagasaki 852-8501 , Japan"},{"name":"Clinical Research Center, Nagasaki University Hospital , 1-7-1 Sakamoto, Nagasaki 852-8501 , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsunori","family":"Yanagihara","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Nagasaki University Graduate School of Biomedical Sciences , 1-7-1 Sakamoto, Nagasaki 852-8501 , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Mukae","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Nagasaki University Hospital , 1-7-1 Sakamoto, Nagasaki 852-8501 , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichi","family":"Izumikawa","sequence":"additional","affiliation":[{"name":"Infection Control and Education Center, Nagasaki University Hospital , 1-7-1 Sakamoto, Nagasaki 852- 8501 , Japan"},{"name":"Department of Infectious Diseases, Nagasaki University Graduate School of Biomedical Sciences , 1-7-1 Sakamoto, Nagasaki 852-8501 , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2023,9,22]]},"reference":[{"key":"2023101317080745100_bib1","doi-asserted-by":"crossref","first-page":"3107","DOI":"10.1128\/AAC.06252-11","article-title":"Cryptococcus neoformans\u2013Cryptococcus gattii species complex: an international study of wild-type susceptibility endpoint distributions and epidemiological cutoff values for amphotericin B and flucytosine","volume":"56","author":"Espinel-Ingroff","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"2023101317080745100_bib2","doi-asserted-by":"crossref","first-page":"5898","DOI":"10.1128\/AAC.01115-12","article-title":"Cryptococcus neoformans\u2013Cryptococcus gattii species complex: an international study of wild-type susceptibility endpoint distributions and epidemiological cutoff values for fluconazole, itraconazole, posaconazole, and voriconazole","volume":"56","author":"Espinel-Ingroff","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"2023101317080745100_bib3","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1128\/AAC.44.6.1544-1548.2000","article-title":"Correlation of fluconazole MICs with clinical outcome in cryptococcal infection","volume":"44","author":"Aller","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"2023101317080745100_bib4","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.1128\/AAC.01520-05","article-title":"Results obtained with various antifungal susceptibility testing methods do not predict early clinical outcome in patients with cryptococcosis","volume":"50","author":"Dannaoui","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"2023101317080745100_bib5","doi-asserted-by":"crossref","first-page":"e2338","DOI":"10.1093\/cid\/ciaa1544","article-title":"Antifungal susceptibility does not correlate with fungal clearance or survival in AIDS-associated cryptococcal meningitis","volume":"73","author":"O'Connor","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2023101317080745100_bib6","doi-asserted-by":"crossref","first-page":"8162096","DOI":"10.1155\/2022\/8162096","article-title":"The predominance of a specific genotype of Cryptococcus neoformans var. Grubii in China and Japan","volume":"2022","author":"Zhu","year":"2022","journal-title":"Comput Math Methods Med"},{"key":"2023101317080745100_bib7","doi-asserted-by":"crossref","first-page":"51","DOI":"10.7883\/yoken.66.51","article-title":"Determination of epidemiology of clinically isolated Cryptococcus neoformans strains in Japan by multilocus sequence typing","volume":"66","author":"Umeyama","year":"2013","journal-title":"Jpn J Infect Dis"},{"key":"2023101317080745100_bib8","doi-asserted-by":"crossref","first-page":"252","DOI":"10.3109\/13693786.2012.708883","article-title":"Multilocus sequence typing of Cryptococcus neoformans in non-HIV associated cryptococcosis in Nagasaki, Japan","volume":"51","author":"Mihara","year":"2013","journal-title":"Med Mycol"},{"key":"2023101317080745100_bib9","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/ja.2015.29","article-title":"Antifungal susceptibilities of Candida, Cryptococcus neoformans and Aspergillus fumigatus from the Asia and Western Pacific region: data from the SENTRY antifungal surveillance program (2010\u20132012)","volume":"68","author":"Pfaller","year":"2015","journal-title":"J Antibiot (Tokyo)"},{"key":"2023101317080745100_bib10","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.diagmicrobio.2015.04.008","article-title":"Isavuconazole, micafungin, and 8 comparator antifungal agents' susceptibility profiles for common and uncommon opportunistic fungi collected in 2013: temporal analysis of antifungal drug resistance using CLSI species-specific clinical breakpoints and proposed epidemiological cutoff values","volume":"82","author":"Pfaller","year":"2015","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2023101317080745100_bib11","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1128\/AAC.00048-11","article-title":"Trends in antifungal drug susceptibility of Cryptococcus neoformans isolates obtained through population-based surveillance in South Africa in 2002\u20132003 and 2007\u20132008","volume":"55","author":"Govender","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"2023101317080745100_bib12","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1186\/s12879-015-1023-8","article-title":"Increasing trend of fluconazole-non-susceptible Cryptococcus neoformans in patients with invasive cryptococcosis: a 12-year longitudinal study","volume":"15","author":"Chen","year":"2015","journal-title":"BMC Infect Dis"},{"key":"2023101317080745100_bib13","first-page":"ofz369","article-title":"Minimum inhibitory concentration distribution of fluconazole against Cryptococcus species and the fluconazole exposure prediction model","volume-title":"Open Forum Infect Dis","author":"Chesdachai","year":"2019"},{"key":"2023101317080745100_bib14","doi-asserted-by":"crossref","first-page":"e1010073","DOI":"10.1371\/journal.ppat.1010073","article-title":"Fungicide effects on human fungal pathogens: cross-resistance to medical drugs and beyond","volume":"17","author":"Bastos","year":"2021","journal-title":"PLoS Pathog"},{"key":"2023101317080745100_bib15","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1007\/s13762-017-1565-y","article-title":"Trends in usage of selected fungicides in Japan between 1962 and 2014: a review","volume":"15","author":"Kaonga","year":"2018","journal-title":"Int J Environ Sci Technol"},{"key":"2023101317080745100_bib16","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/S1473-3099(17)30243-8","article-title":"Global burden of disease of HIV-associated cryptococcal meningitis: an updated analysis","volume":"17","author":"Rajasingham","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"2023101317080745100_bib17","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1086\/368091","article-title":"The changing epidemiology of cryptococcosis: an update from population-based active surveillance in 2 large metropolitan areas, 1992\u20132000","volume":"36","author":"Mirza","year":"2003","journal-title":"Clin Infect Dis."},{"key":"2023101317080745100_bib18","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1007\/s40588-017-0064-8","article-title":"Cryptococcosis today: it is not all about HIV infection","volume":"4","author":"O'Halloran","year":"2017","journal-title":"Curr Clin Microbiol Rep"}],"container-title":["Medical Mycology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/mmy\/advance-article-pdf\/doi\/10.1093\/mmy\/myad100\/51728567\/myad100.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mmy\/article-pdf\/61\/10\/myad100\/52070584\/myad100.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mmy\/article-pdf\/61\/10\/myad100\/52070584\/myad100.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T17:09:35Z","timestamp":1697216975000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/mmy\/article\/doi\/10.1093\/mmy\/myad100\/7280760"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,22]]},"references-count":18,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10,5]]}},"URL":"https:\/\/doi.org\/10.1093\/mmy\/myad100","relation":{},"ISSN":["1369-3786","1460-2709"],"issn-type":[{"type":"print","value":"1369-3786"},{"type":"electronic","value":"1460-2709"}],"subject":[],"published-other":{"date-parts":[[2023,10]]},"published":{"date-parts":[[2023,9,22]]},"article-number":"myad100"}}